Absci (ABSI) Cash And Cash Equivalents : $47.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Absci Cash And Cash Equivalents?

Absci's quarterly cash and cash equivalents increased from Sep. 2024 ($38.20 Mil) to Dec. 2024 ($41.21 Mil) and increased from Dec. 2024 ($41.21 Mil) to Mar. 2025 ($47.00 Mil).

Absci's annual cash and cash equivalents increased from Dec. 2022 ($59.96 Mil) to Dec. 2023 ($72.36 Mil) but then declined from Dec. 2023 ($72.36 Mil) to Dec. 2024 ($41.21 Mil).

Absci Cash And Cash Equivalents Historical Data

The historical data trend for Absci's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Cash And Cash Equivalents Chart

Absci Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

69.87

252.57

59.96

72.36

41.21

Absci Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															58.83	42.94	38.20	41.21	47.00

Absci Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Absci (NAS:ABSI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Absci Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Absci's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Absci Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683

Website

https://www.absci.com

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Executives

Zachariah Jonasson	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Phoenix Venture Partners Ii Lp	10 percent owner	1700 EL CAMINO REAL, SUITE 355, SAN MATEO CA 94402
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Frans Van Houten	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj	director	400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman	officer: General Counsel	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick	officer: VP, CCPAO	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh	director	C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Sean Mcclain	director, 10 percent owner, officer: President and Chief Executive	18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Karen K Mcginnis	director	INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p.	director, 10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc	10 percent owner	1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402